Natelson 2015.

Study characteristics
Methods	Design: parallel Duration: 8 weeks Assessment: baseline and post‐intervention Country: USA
Participants	Pain condition: fibromyalgia Population: adults aged 18‐68 with fibromyalgia Minimum pain intensity: no Inclusion criteria Fibromyalgia meeting the ACR criteria > 10 of 18 tender points, points were considered tender if they were reported to be ≥ 2 on a pain intensity VAS from 0‐10 reported by patients Exclusion criteria Severe physical and mental health comorbidities Total participants randomised: 34 Age in years (mean, SD): 46.8 Gender: 33/34 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 17 Inert Identical appearance and matched dosing schedule Milnacipran 100 mg n = 17 SNRI Forced titration to fixed dose
Outcomes	Pain intensity AEs SAEs Withdrawal
Missing data methods	Completer‐only analysis
Funding source	Part funded by pharmaceutical: "This work was supported by a Forest Laboratories Investigator‐initiated grant to B.H.N., and, in part, by National Institutes of Mental Health (NIMH) grant R01 MH100005 to D.C.S."
Conflicts of interest	"J.D.C. has been a speaker for Pfizer, Forest, Bristol Myers Squibb, Glaxo Smith Kline, Eli Lilly, and Sunovion. He has received grants from Pfizer Pharmaceuticals, GSK, Corcept, and Neurocrine. There were no other conflicts of interest in doing this research. This work was supported by a Forest Laboratories Investigator‐initiated grant to B.H.N., and, in part, by National Institutes of Mental Health (NIMH) grant R01 MH100005 to D.C.S. The sources of funding had no involvement in any of the aspects of running this study, analyzing the data, or preparing this manuscript."
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Low risk	Mount Sinai Beth Israel Pharmacy dispensed the drug or placebo according to the randomisation list in sequential order.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, with identical study drugs and matched dosage schedule
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer‐only analysis Attrition Total: 8/34 (23.5%) Placebo: 4/17 (23.5%) Milnacipran 100 mg: 4/17 (23.5%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified